Ubix Therapeutics
Latest round
- Series C
Last raised
- Jul 2023
Total raised
- $27M
Investors
- 12
About Ubix Therapeutics
Founded in 2018 and based in Seoul, South Korea, Ubix Therapeutics is a pharmaceutical research and development company specializing in the technology known as Proteolysis Targeting Chimera (PROTAC), which is an inhibitor cell technology to treat cancer and intractable disease. The company offers research and development of new drug services.
Who invested in Ubix Therapeutics
12 investors across 3 rounds
See all investors in Ubix Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ubix Therapeutics
Who invested in Ubix Therapeutics?
Ubix Therapeutics has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ubix Therapeutics raised?
Ubix Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Ubix Therapeutics last raise money?
Ubix Therapeutics's most recent round on record is a Series C, in Jul 2023.
What does Ubix Therapeutics do?
Founded in 2018 and based in Seoul, South Korea, Ubix Therapeutics is a pharmaceutical research and development company specializing in the technology known as Proteolysis Targeting Chimera (PROTAC), which is an inhibitor cell technology to treat cancer and intractable disease.
Where is Ubix Therapeutics headquartered?
Ubix Therapeutics is headquartered in Seoul, South Korea.
Which VCs invest in companies like Ubix Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Ubix Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Ubix Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.